| Keywords: |
treatment response; lenalidomide; prednisone; thalidomide; clinical feature; disease course; review; salvage therapy; cisplatin; doxorubicin; placebo; cancer combination chemotherapy; monotherapy; cancer adjuvant therapy; chemotherapy, adjuvant; drug megadose; antineoplastic agent; clinical practice; low drug dose; bortezomib; proteasome inhibitor; multiple myeloma; etoposide; antineoplastic combined chemotherapy protocols; peripheral neuropathy; maintenance therapy; recurrence; bisphosphonates; c-reactive protein; combination chemotherapy; cytogenetics; immunomodulatory drugs; nccn clinical practice guidelines; novel therapies; primary amyloidosis; stem cell transplant; supportive therapies; bendamustine; cyclophosphamide; dexamethasone; melphalan; vincristine; deep vein thrombosis; plasmacytoma; practice guideline; stem cell transplantation; pneumonia; drug fatality; disease progression; adjuvant chemotherapy; recurrent disease; diagnostic test; venous thromboembolism; nccn guidelines; waldenstr; asymptomatic disease; asymptomatic diseases
|
